We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Susceptibility Genes Distinct from Severity Genes in Crohn's Disease

By LabMedica International staff writers
Posted on 17 Jan 2017
The group of 170 gene variants that have been linked to the development of Crohn's disease has been found to operate independently from a second group of four variants, which determines how severe the disease will be.

Severity of an immune-mediated disease such as Crohn's may vary substantially between patients for reasons that are poorly understood. More...
Familial studies support a genetic contribution to disease severity, but little evidence has been found for a proposed association between gene variants linked to severity and those linked to susceptibility.

To better characterize how genetic variation influences the severity of the disease, investigators at the University of Cambridge performed a within-cases genome-wide association study in two cohorts that comprised 2,700 individuals, who had been selected because they had experienced particularly mild or particularly aggressive forms of Crohn's disease.

The investigators identified four genome-wide significant loci, none of which showed any association with disease susceptibility. Conversely, the aggregated effect of all 170 disease susceptibility loci was not associated with disease severity.

"This shows us that the genetic architecture of disease outcome is very different to that of disease risk," said senior author Dr. Kenneth G. C. Smith, professor of medicine at the University of Cambridge. "In other words, the biological pathways driving disease progression may be very different to those that initiate the disease itself. This was quite unexpected. Past work has focused on discovering genes underlying disease initiation, and our work suggests these may no longer be relevant by the time a patient sees the doctor. We may have to consider directing new therapies to quite different pathways in order to treat established disease"

The study was published in the January 9, 2017, online edition of the journal Nature Genetics.


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Chromogenic Culture System
InTray™ COLOREX™ ECC
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.